Amgen(AMGN)

Search documents
Amgen Inc. (AMGN) 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Transcript)
2023-05-31 18:20
Amgen Inc. (NASDAQ:AMGN) 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA May 31, 2023 11:00 AM ET Company Participants David Reese - Executive Vice President of R&D Arvind Sood - Vice President of Investor Relations Conference Call Participants Yaron Werber - TD Cowen Yaron Werber Okay. Good morning, everybody. We're just going to wait five seconds or so to let everybody scroll in. And then we will get started. So good morning, everybody, and thank you once again for joining us at the 4th Ann ...
Amgen Inc. (AMGN) Presents at BofA Securities 2023 Health Care Conference (Transcript)
2023-05-13 23:00
Amgen Inc. (NASDAQ:AMGN) BofA Securities 2023 Health Care Conference May 9, 2023 11:00 AM ET Company Participants Peter Griffith - CFO Dave Reese - EVP, R&D Conference Call Participants Dan Lundquist - Ban of America Dan Lundquist Hello. Good morning, everybody. Thank you for coming out to Las Vegas for the 2023 Healthcare Conference. You are at the first session with Amgen. I'm very pleased today to be joined by Peter Griffith, the CFO; and Dave Reese, Executive VP of R&D, here on stage today. We do have a ...
Amgen(AMGN) - 2023 Q1 - Quarterly Report
2023-04-27 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☑ EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES ☐ EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or org ...
Amgen(AMGN) - 2022 Q4 - Annual Report
2023-02-08 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organizat ...
Amgen(AMGN) - 2022 Q3 - Quarterly Report
2022-11-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I. ...
Amgen(AMGN) - 2022 Q2 - Quarterly Report
2022-08-04 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q or (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I.R.S. ...
Amgen(AMGN) - 2022 Q1 - Quarterly Report
2022-04-27 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-37702 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of incorporation or organization)(I.R.S. ...
Amgen(AMGN) - 2021 Q4 - Annual Report
2022-02-15 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |----------------------------------------------------------------------------|------------------------------------------| | Amgen Inc. (Exact name of registrant as specified in | c ...